The convertible notes are due 2029

Davis Polk advised the representatives of the several initial purchasers in connection with a Rule 144A offering by Evolent Health, Inc. of $402.5 million aggregate principal amount of its 3.50% senior convertible notes due 2029.

Based in Arlington, Virginia, Evolent Health partners with leading health systems to drive value-based care transformation. By providing clinical, analytical and financial capabilities, Evolent Health helps physicians and health systems achieve superior quality and cost results. Evolent Health’s approach breaks down barriers, aligns incentives and powers a new model of care delivery, resulting in meaningful alignment between providers, payers, physicians and patients.

The Davis Polk corporate team included partner Yasin Keshvargar, counsel John H. Runne and associates Livia Maas and Andrew Masaru Orita. The equity derivatives team included partner Mark M. Mendez and associates Stockton Bullitt and Jonathan Schlecht. Partner Pritesh P. Shah provided intellectual property advice. Partner Michael Farber and associate William Liang provided tax advice. All members of the Davis Polk team are based in the New York office.